Drug Trial Radar · NCT07815665
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
800
Planned (sponsor's estimate)
Start
Sep 10, 2026
Primary completion
Oct 31, 2030
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Summit TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Randomized, Open-Label, Multicenter, Phase 2/3 Clinical Study of Ivonescimab in Combination with Enfortumab Vedotin vs Pembrolizumab in Combination with Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi-GU1)
Conditions
- Metastatic Urothelial Carcinoma
- Metastatic Urothelial Carcinoma (UC)
Interventions
Ivonescimab Dose 1Drug
First ivonescimab dose to be tested in Phase 2
enfortumab vedotin (EV)Drug
Standard of care therapy
PembrolizumabDrug
200 mg
Ivonescimab Dose 2Drug
Second Ivonescimab dose to be tested in Phase 2 part of the study
Ivonescimab RP3DDrug
Recommended Phase 3 dose of Ivonescimab after Phase 2 data analysis
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2 Primary Outcome MeasureTime frame: Through 90 days after the last study treatment
- Phase 2 Primary Outcome MeasureTime frame: From first dose until approximately 30 days after the last study treatment, assessed up to 3 years
- Phase 2 Primary Outcome measureTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years
- Phase 2 Primary Outcome MeasureTime frame: From first dose until end of treatment, assessed up to 3 years
- Phase 3 Primary Outcome MeasureTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years.
- Phase 3 Primary Outcome MeasureTime frame: From date of randomization until the end of study, assessed up to 4 years
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona · Not yet recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
Washington D.C., District of Columbia · Not yet recruiting
Research Site
Jacksonville, Florida · Not yet recruiting
Research Site
Rochester, Minnesota · Not yet recruiting
Research Site
Nashville, Tennessee · Not yet recruiting
Research Site
Spokane, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.